Catch up on the state of the art in Thoracic Surgery

 

The most up-to-date surgical management for lung cancer, the mediastinum and pleura, and the esophagus, will be featured in Sunday’s full-day symposium “Thoracic Surgery 2017 – State of the Art.”

“We will cover not only standard practice and a lot of the major clinical issues that come up in general thoracic surgery but also discuss new developments and directions for thoracic diseases,” said Seth D. Force, MD, of Emory University, course co-chair. “It’s hard for everyone to stay up to date on everything, especially with a lot of the modern techniques and changes in treatment plans. Things are changing pretty quickly. Presentations by the leading experts in our field will help bring participants up to speed on the latest treatments for different thoracic diseases.”

“There’s no question that everyone who attends this session will take home a few things that will change their practice, whether it be in the work-up, in the operative management or in the postoperative follow-up, and the adjuvant therapy for these diseases,” added course co-chair Moishe Liberman, MD, PhD, of the University of Montreal. “When you have an all-star cast of speakers who are the experts in their field, everyone takes home something new from these sessions no matter how experienced they are.”

The symposium will kick off with a presentation by Betty Tong, MD, of Duke University, on setting up a lung cancer screening program. “[Screening] has really become an important concept in the outpatient thoracic practice,” Dr. Force said. Other presenters giving talks in this section on solitary pulmonary nodule and screening will discuss who gets followed in lung cancer screening programs, management of screen-detected lesions, and diagnostic modality options for suspicious lesions. “There’s a lot of buzz around lung cancer screening as well as what to do with small nodules that are found in these screening programs – how to deal with them, what they mean and what’s the best surgical approach,” Dr. Liberman said.

The next section of the course, on controversial and high-risk patients with lung cancer, will feature presentations on how to define physiological high risk; evidence-supported use of sublobar resection, MITS and brachytherapy; state of the science for SBRT versus resection in clinical stage 1, and a pro-con debate on when surgery is indicated for patients with N2 disease.

The third portion of the symposium will dive into state-of-the art management of the mediastinum and pleura, including talks on surgery in exceptional myasthenia patients; evolved management of the anterior mediastinal mass; surgery plus other treatments in the exceptional thymoma patient; best strategy for classic presentation of malignant mesothelioma; and the best intervention algorithm for malignant pleural effusion.

The program will conclude with a series of talks on the esophagus, including exploring the limits of esophageal-sparing therapy for high-grade dysplasia and T1a adenocarcinoma; who is and is not a candidate for trimodality therapy in stage III cancer; minimally invasive esophagectomt, thoracoscopic esophagectomy and Ivor Lewis surgical approaches; and surgery for complex patients with achalasia, followed by a panel discussion.

“We really hope and expect this will be an interactive session with a lot of participant questions, feedback and back and forth discussion,” Dr. Force said. “Attending the session will allow surgeons to either set up or make sure they have a modern thoracic practice. It will help them ensure they’re providing the most up-to-date treatment and diagnostic options for their patients.”
 

 

The most up-to-date surgical management for lung cancer, the mediastinum and pleura, and the esophagus, will be featured in Sunday’s full-day symposium “Thoracic Surgery 2017 – State of the Art.”

“We will cover not only standard practice and a lot of the major clinical issues that come up in general thoracic surgery but also discuss new developments and directions for thoracic diseases,” said Seth D. Force, MD, of Emory University, course co-chair. “It’s hard for everyone to stay up to date on everything, especially with a lot of the modern techniques and changes in treatment plans. Things are changing pretty quickly. Presentations by the leading experts in our field will help bring participants up to speed on the latest treatments for different thoracic diseases.”

“There’s no question that everyone who attends this session will take home a few things that will change their practice, whether it be in the work-up, in the operative management or in the postoperative follow-up, and the adjuvant therapy for these diseases,” added course co-chair Moishe Liberman, MD, PhD, of the University of Montreal. “When you have an all-star cast of speakers who are the experts in their field, everyone takes home something new from these sessions no matter how experienced they are.”

The symposium will kick off with a presentation by Betty Tong, MD, of Duke University, on setting up a lung cancer screening program. “[Screening] has really become an important concept in the outpatient thoracic practice,” Dr. Force said. Other presenters giving talks in this section on solitary pulmonary nodule and screening will discuss who gets followed in lung cancer screening programs, management of screen-detected lesions, and diagnostic modality options for suspicious lesions. “There’s a lot of buzz around lung cancer screening as well as what to do with small nodules that are found in these screening programs – how to deal with them, what they mean and what’s the best surgical approach,” Dr. Liberman said.

The next section of the course, on controversial and high-risk patients with lung cancer, will feature presentations on how to define physiological high risk; evidence-supported use of sublobar resection, MITS and brachytherapy; state of the science for SBRT versus resection in clinical stage 1, and a pro-con debate on when surgery is indicated for patients with N2 disease.

The third portion of the symposium will dive into state-of-the art management of the mediastinum and pleura, including talks on surgery in exceptional myasthenia patients; evolved management of the anterior mediastinal mass; surgery plus other treatments in the exceptional thymoma patient; best strategy for classic presentation of malignant mesothelioma; and the best intervention algorithm for malignant pleural effusion.

The program will conclude with a series of talks on the esophagus, including exploring the limits of esophageal-sparing therapy for high-grade dysplasia and T1a adenocarcinoma; who is and is not a candidate for trimodality therapy in stage III cancer; minimally invasive esophagectomt, thoracoscopic esophagectomy and Ivor Lewis surgical approaches; and surgery for complex patients with achalasia, followed by a panel discussion.

“We really hope and expect this will be an interactive session with a lot of participant questions, feedback and back and forth discussion,” Dr. Force said. “Attending the session will allow surgeons to either set up or make sure they have a modern thoracic practice. It will help them ensure they’re providing the most up-to-date treatment and diagnostic options for their patients.”
 

 

The most up-to-date surgical management for lung cancer, the mediastinum and pleura, and the esophagus, will be featured in Sunday’s full-day symposium “Thoracic Surgery 2017 – State of the Art.”

“We will cover not only standard practice and a lot of the major clinical issues that come up in general thoracic surgery but also discuss new developments and directions for thoracic diseases,” said Seth D. Force, MD, of Emory University, course co-chair. “It’s hard for everyone to stay up to date on everything, especially with a lot of the modern techniques and changes in treatment plans. Things are changing pretty quickly. Presentations by the leading experts in our field will help bring participants up to speed on the latest treatments for different thoracic diseases.”

“There’s no question that everyone who attends this session will take home a few things that will change their practice, whether it be in the work-up, in the operative management or in the postoperative follow-up, and the adjuvant therapy for these diseases,” added course co-chair Moishe Liberman, MD, PhD, of the University of Montreal. “When you have an all-star cast of speakers who are the experts in their field, everyone takes home something new from these sessions no matter how experienced they are.”

The symposium will kick off with a presentation by Betty Tong, MD, of Duke University, on setting up a lung cancer screening program. “[Screening] has really become an important concept in the outpatient thoracic practice,” Dr. Force said. Other presenters giving talks in this section on solitary pulmonary nodule and screening will discuss who gets followed in lung cancer screening programs, management of screen-detected lesions, and diagnostic modality options for suspicious lesions. “There’s a lot of buzz around lung cancer screening as well as what to do with small nodules that are found in these screening programs – how to deal with them, what they mean and what’s the best surgical approach,” Dr. Liberman said.

The next section of the course, on controversial and high-risk patients with lung cancer, will feature presentations on how to define physiological high risk; evidence-supported use of sublobar resection, MITS and brachytherapy; state of the science for SBRT versus resection in clinical stage 1, and a pro-con debate on when surgery is indicated for patients with N2 disease.

The third portion of the symposium will dive into state-of-the art management of the mediastinum and pleura, including talks on surgery in exceptional myasthenia patients; evolved management of the anterior mediastinal mass; surgery plus other treatments in the exceptional thymoma patient; best strategy for classic presentation of malignant mesothelioma; and the best intervention algorithm for malignant pleural effusion.

The program will conclude with a series of talks on the esophagus, including exploring the limits of esophageal-sparing therapy for high-grade dysplasia and T1a adenocarcinoma; who is and is not a candidate for trimodality therapy in stage III cancer; minimally invasive esophagectomt, thoracoscopic esophagectomy and Ivor Lewis surgical approaches; and surgery for complex patients with achalasia, followed by a panel discussion.

“We really hope and expect this will be an interactive session with a lot of participant questions, feedback and back and forth discussion,” Dr. Force said. “Attending the session will allow surgeons to either set up or make sure they have a modern thoracic practice. It will help them ensure they’re providing the most up-to-date treatment and diagnostic options for their patients.”